Shanghai Desano Pharmaceuticals Co. Ltd.

The main purpose of this study is to collect post-marketing clinical safety data of dogliflozin and to evaluate the long-term safety of this product in a larger sample of type 2 diabetes population.

Primary objective: To investigate the pharmacokinetic characteristics of ritonavir tablets (specification: 100 mg) produced by Shanghai Desano Biopharmaceutical Co., Ltd. and ritonavir tablets (Norvir®, specification: 100 mg) held by licensee AbbVie Deutschland GmbH & Co. KG. in healthy Chinese subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and reference preparation of ritonavir tablets (specification: 100 mg) in healthy Chinese subjects after a single oral administration.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of Lamivudine-Tenofovir Tablets (Specifications: Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg) produced by Jiangsu Chengkang Pharmaceutical Co., Ltd. (Owner: Shanghai Desano Biopharmaceutical Co., Ltd.) and Lamivudine-Tenofovir Tablets (Trade name: Cimduo®, Specifications: Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg) produced by Mylan Laboratories Ltd. (Trade name: Cimduo®, Specifications: Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg) in healthy Chinese subjects after a single oral dose under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and reference preparation of Lamivudine-Tenofovir Tablets (Specifications: Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg) taken orally as a single dose in healthy Chinese subjects.